PolarityBio Phase 3 DFU data wins First-to-Podium slot at SAWC 2026
PolarityBio has secured a First-to-Podium presentation slot at the Symposium on Advanced Wound Care (SAWC) Fall 2026 in Las Vegas for its Phase 3 COVER DFUS II trial, which is evaluating SkinTE, the company's autologous cutaneous multicellular therapy, in patients with non-healing Wagner Grade 1 diabetic foot ulcers (DFUs). The presentation, scheduled for 16 October, will be delivered by the trial's Study Chair, Robert S. Kirsner, MD, PhD, of the University of Miami Miller School of Medicine, and will mark the first public disclosure of pivotal Phase 3 results for the programme.
The SAWC First-to-Podium programme is reserved for previously unpublished data judged by the conference scientific committee to have meaningful potential to alter clinical practice. Selection carries weight in wound care circles, where such podium presentations frequently precede or accompany regulatory filings.
Trial design and regulatory status
COVER DFUS II (NCT06140303) enrolled 120 patients across multiple US sites over 14 months, randomised 1:1 to SkinTE plus standard of care versus standard of care alone. Participants were required to have had a DFU persisting for at least four weeks, and all completed a two-week run-in period under rigorous standard-of-care conditions. To qualify for randomisation, wound area could not decrease by more than 30% during that window, a design feature intended to isolate wounds that are genuinely treatment-resistant. The primary efficacy endpoint was complete wound closure within 12 weeks, with a 24-week follow-up window.
Kirsner described the strict run-in design as central to the trial's scientific credibility. "Patients with chronic, non-healing diabetic foot ulcers face severe clinical challenges and high risks of amputation," he said. "The study design ensured we evaluated SkinTE in patients with advanced diabetic foot pathology truly in need of advanced treatment."
PolarityBio's Biologics Licence Application for SkinTE has been accepted by the FDA for Priority Review, with a PDUFA date of 16 March 2027. The programme holds both Regenerative Medicine Advanced Therapy (RMAT) and Breakthrough Therapy designations. The company noted that the topline data itself has not yet been released publicly and will be disclosed for the first time during the SAWC presentation.
Market context and competitive landscape
Diabetic foot ulcers represent a substantial and poorly served clinical challenge. An estimated 15–25% of people living with diabetes will develop a DFU during their lifetime, and the risk of lower-limb amputation in patients with non-healing wounds is significant. The wound care biologics market has attracted a number of competitors, including established products such as Organogenesis's Apligraf and MiMedx's EpiFix, both of which are acellular or allogeneic in nature. SkinTE's autologous, multicellular approach occupies a distinct position from these existing therapies, though head-to-head comparative data against current standards has not been made available.
Priority Review status compresses the FDA's standard 12-month review to six months, meaning a potential approval decision could arrive in the first quarter of 2027. SkinTE is also being evaluated for venous leg ulcers and pressure injuries, which would, if approved in those indications, meaningfully broaden the addressable market. Investors and clinicians will watch closely for the complete dataset, including the primary endpoint readout, any subgroup analyses, and safety signals, when Kirsner takes the podium on 16 October.